1. Home
  2. PHUN vs ANIX Comparison

PHUN vs ANIX Comparison

Compare PHUN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phunware Inc.

PHUN

Phunware Inc.

HOLD

Current Price

$2.03

Market Cap

44.4M

Sector

Technology

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.71

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHUN
ANIX
Founded
2009
1982
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.4M
88.8M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
PHUN
ANIX
Price
$2.03
$2.71
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$7.25
$8.67
AVG Volume (30 Days)
131.6K
99.1K
Earning Date
05-14-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
39.36
12.82
EPS
N/A
N/A
Revenue
$30,883,000.00
$210,000.00
Revenue This Year
$89.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.57
N/A
52 Week Low
$1.56
$2.44
52 Week High
$3.88
$5.46

Technical Indicators

Market Signals
Indicator
PHUN
ANIX
Relative Strength Index (RSI) 49.66 47.43
Support Level $1.79 $2.65
Resistance Level $2.28 $3.12
Average True Range (ATR) 0.11 0.12
MACD -0.01 -0.02
Stochastic Oscillator 42.11 42.86

Price Performance

Historical Comparison
PHUN
ANIX

About PHUN Phunware Inc.

Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: